Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | GABRP | O00591 | 1/20 | 0.33 |
| ▸ | GABRD | O14764 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL264366 | 0.79 | NPSR1 (0.48) | ALDH1A1SMN1; SMN2GRM5RAB9AMEN1 | |
| SCHEMBL2373944 | 0.78 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2MAPTPIN1GRM5 | |
| SCHEMBL29625359 | 0.77 | GABRP (0.47) | ALDH1A1SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL1759159 | 0.77 | GRM5 (0.53) | ALDH1A1SMN1; SMN2MAPTPIN1GRM5 | |
| SCHEMBL262422 | 0.77 | GABRP (0.47) | ALDH1A1SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL4917922 | 0.75 | MEN1 (0.55) | ALDH1A1SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL9951754 | 0.75 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2MAPTPIN1GRM5 | |
| SCHEMBL3576485 | 0.75 | GRM5 (0.54) | ALDH1A1SMN1; SMN2MAPTPIN1GRM5 | |
| SCHEMBL20209381 | 0.75 | SMN1; SMN2 (0.39) | ALDH1A1SMN1; SMN2MAPTPIN1GRM5 | |
| SCHEMBL1405829 | 0.75 | GRM5 (0.40) | ALDH1A1SMN1; SMN2MAPTPIN1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024509-B2 | Therapeutic compounds as inhibitors of the orexin-1 receptor | C4X DISCOVERY LIMITED (GB) | 2024-07-02 | — | — | US | disclosed |
| US-20170291897-A1 | THERAPEUTIC COMPOUNDS AS INHIBITORS OF THE OREXIN-1 RECEPTOR | INDIVIOR INC. | 2017-10-12 | — | — | US | disclosed |
| EP-2794593-B1 | SPIRO AMINIC COMPOUNDS AS OREXIN ANTAGONISTS | Rottapharm Biotech Srl (IT) | 2017-02-01 | — | — | EP | disclosed |
| US-9493438-B2 | 4,4-difluoro-piperidine-compounds | ROTTAPHARM S.R.L. (IT) | 2016-11-15 | — | — | US | disclosed |
| EP-2820007-B1 | 4,4-DIFLUORO-PIPERIDINE-COMPOUNDS | Rottapharm Biotech Srl (IT) | 2016-04-20 | — | — | EP | disclosed |
| WO-2016034882-A1 | THERAPEUTIC COMPOUNDS AS INHIBITORS OF THE OREXIN-1 RECEPTOR | C4X DISCOVERY LIMITED (GB) | 2016-03-10 | — | — | WO | disclosed |
| US-9062033-B2 | Chemical compounds | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-06-23 | — | — | US | disclosed |
| US-20150051226-A1 | 4,4-DIFLUORO-PIPERIDINE-COMPOUNDS | ROTTAPHARM S.P.A. (IT) | 2015-02-19 | — | — | US | disclosed |
| EP-2820007-A1 | 4,4-DIFLUORO-PIPERIDINE-COMPOUNDS | Rottapharm Biotech S.r.l. (IT) | 2015-01-07 | — | — | EP | disclosed |
| US-20140357653-A1 | CHEMICAL COMPOUNDS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2014-12-04 | — | — | US | disclosed |
| WO-2013127913-A1 | 4,4-DIFLUORO-PIPERIDINE-COMPOUNDS | ROTTAPHARM S.P.A. (IT) | 2013-09-06 | — | — | WO | disclosed |
| WO-2013092893-A1 | CHEMICAL COMPOUNDS | ROTTAPHARM SPA (IT) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013050938-A1 | 3,7-DIAZABICYCLO[3.3.1]NONANE AND 9-OXA-3,7-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-04-11 | — | — | WO | disclosed |
| CN-101133027-B | Pyridine-2-carboxamide derivatives as mglur5 antagonists | HOFFMANN LA ROCHE | 2011-03-30 | — | — | CN | disclosed |
| US-20080269256-A1 | PYRIDINE-2-CARBOXYAMIDE DERIVATIVES | JAESCHKE GEORG | 2008-10-30 | — | — | US | disclosed |
| US-7414060-B2 | Pyridine-2-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-08-19 | — | — | US | disclosed |
| CN-101133027-A | Pyridine-2-carboxamide derivatives as mglur5 antagonists | HOFFMANN LA ROCHE (CH) | 2008-02-27 | — | — | CN | disclosed |
| EP-1858854-A1 | PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006094639-A1 | PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-09-14 | — | — | WO | disclosed |
| US-20060199960-A1 | e.g. 6-Methyl-3-(pyridin-3-ylamino)-pyridine-2-carboxylic acid (4-methyl-thiazol-2-yl)-amide; metabotropic glutamate receptor antagonists (mGluR); central nervous system disorders, antidepressant, anxiolytc agent; psychosis, epilepsy, schizophrenia, Alzheimer's disease, cognitive disorders | HOFFMANN-LA ROCHE INC. | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269256-A1 | PYRIDINE-2-CARBOXYAMIDE DERIVATIVES | CNR2, CNR1, CHRNA2 | ALDH1A1 656/4885SMN1; SMN2 181/4885MAPT 627/4885 |
| US-12024509-B2 | Therapeutic compounds as inhibitors of the orexin-1 receptor | HCRTR1, HCRTR2, NPY1R | ALDH1A1 1458/4885SMN1; SMN2 2154/4885MAPT 557/4885 |
| US-20170291897-A1 | THERAPEUTIC COMPOUNDS AS INHIBITORS OF THE OREXIN-1 RECEPTOR | HCRTR1, HCRTR2, NPY1R | ALDH1A1 1458/4885SMN1; SMN2 2154/4885MAPT 557/4885 |
| US-20060199960-A1 | e.g. 6-Methyl-3-(pyridin-3-ylamino)-pyridine-2-carboxylic acid (4-methyl-thiazol-2-yl)-amide; metabotropic glutamate receptor antagonists (mGluR); central nervous system disorders, antidepressant, anxiolytc agent; psychosis, epilepsy, schizophrenia, Alzheimer's disease, cognitive disorders | GRM3, GRM2, GRM1 | ALDH1A1 2246/4885SMN1; SMN2 2636/4885MAPT 81/4885 |
| US-20150051226-A1 | 4,4-DIFLUORO-PIPERIDINE-COMPOUNDS | SLCO4C1, PAICS, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ALDH1A1 1187/4885SMN1; SMN2 2505/4885MAPT 4402/4885 |
| US-20140357653-A1 | CHEMICAL COMPOUNDS | HCRTR2, HCRTR1, NPY1R | ALDH1A1 1588/4885SMN1; SMN2 2688/4885MAPT 4402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.